Key stats
About ProShares Ultra Nasdaq Biotechnology
Expense ratio
0.95%
Home page
Inception date
Apr 7, 2010
BIB, having been around since 2010, is a leveraged play on the NASDAQ Biotechnology Index (which is also tracked in unlevered form by iShares' IBB), and is heavily focused on NASDAQs biotechnology and pharmaceutical firms with a large-cap bias. The fund gains its 2x leveraged exposure to the index through several financial instruments (i.e. equity securities, derivatives and money-market instruments), and rebalances its exposure daily. Like all geared funds that rebalance daily, BIB is meant for short-term trading since compounding effects over the long-term could create vast differences from expected returnsfor good or for ill.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Government
Stocks76.78%
Health Technology74.91%
Commercial Services1.11%
Technology Services0.40%
Health Services0.33%
Process Industries0.03%
Bonds, Cash & Other23.22%
Government15.66%
Cash7.55%
Miscellaneous0.01%
Stock breakdown by region
North America99.80%
Europe0.20%
Latin America0.00%
Asia0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history